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ABSTRACT: The pressure to deliver new medicines to the patient continues to grow along with increases in compound fail-
ure rate; thus, putting the current R&D model at risk. Analysis has shown that increasing the three-dimensionality of poten-
tial drug candidates decreases the risk of failure and improves binding selectivity and frequency. For this reason many 
workers have taken a new look at the power of photochemistry, as a means to generate novel sp3 rich scaffolds for use in 
drug discovery programs. Here we report the design, synthesis and computational structural analysis of a series of 2,4-
methanoprolines having inherent 3D character (PMI and PBF Scores) significantly higher than that of the broader AbbVie 
Rule of 3 (Ro3) collection.
In their seminal paper entitled “Escape from Flatland: In-
creasing Saturation as an Approach to Improving Clinical 
Success” Lovering et al hypothesized that the shift to high-
throughput synthetic practices had resulted in more achi-
ral, aromatic compounds.1 This was supported by Walters 
et al who analysed the types of molecules that had been 
made by medicinal chemists over the 50 years preceding 
2009. It showed quite conclusively the dramatic rise in the 
proportion of molecules containing sp2 - sp2 couplings. The 
authors attributed this trend away from sp3 character to 
the introduction of new methods for sp2 - sp2 couplings, 
and the adaptation of these methods to high-throughput 
synthesis, utilised widely in optimisation programs and in 
archive “enrichment” campaigns (Figure 1).2  
Lovering et al focussed on carbon bond saturation as de-
fined by fraction sp3 (Fsp3) where Fsp3 = (number of sp3 
hybridized carbons/total carbon count) as a simple and 
interpretable measurement of the complexity of molecules 
prepared as potential drug candidates. They went on to 
demonstrate that complexity (as measured by Fsp3) corre-
lates with success as compounds transition from discov-
ery, through clinical testing, to drugs (see Figure 2). They 
further demonstrated that saturation correlates with solu-
bility, an experimental physical property important to suc-
cess in the drug discovery setting.1  
In a later paper, Lovering described how increasing com-
plexity reduces promiscuity and Cyp450 inhibition. In-
creased promiscuity has been linked to toxicity and candi-
date failure.3  
 
Figure 1. Influence of sp2 – sp2 coupling chemistries on the 
molecules published in the Journal of Medicinal Chemistry 
between 1959 and 2009. Data are shown as the fraction of 
molecules published in each 5-year period containing at least 
one acyclic–aromatic carbon–carbon bond. Reprinted from ref 




Figure 2. Mean Fsp3 for compounds in different stages of de-
velopment. **P value <0.001. Reprinted from ref (1). Copy-
right 2009, American Chemical Society. 
 
Further to the positive impact of increasing fraction sp3 
(Fsp3) on attrition rates, Clemons et al examined com-
pounds from different sources (commercial, academic, 
natural) for their protein-binding behaviours and found 
that these behaviours correlate with general trends in ste-
reochemical and shape descriptors for these compound 
collections. Increasing the content of sp3-hybridized and 
stereogenic atoms relative to compounds from commercial 
sources, which comprise the majority of current screening 
collections, improved binding selectivity and frequency.4 
A well-established approach to the generation of high qual-
ity small molecular weight leads for drug discovery pro-
grams is by the application of fragment based methods. We 
were prompted to look at synthetic methodologies that 
could be utilised to efficiently generate novel, complex, sp3 
rich fragments. For a number of years, we have been inves-
tigating the use of photochemistry, in particular [2+2] cy-
cloadditions, as a source of desirable starting points for 
medicinal chemistry.5 We have, like other workers, fo-
cussed some of our efforts on analogues of 2,4-
methanoproline 1. 2,4-methanoproline 1 was first isolated 
from the seeds of Ateleia herbert smithii Pittier, a tree 
found in Costa Rica,6 and is prepared in a simple sequence 
of reactions from ethyl pyruvate 2 or serine 3 (Scheme 1) 
via intramolecular [2 + 2] olefin photocycloaddition reac-
tions.7,8 The utility and conformational properties of 2,4-
methanoproline 1 as a replacement for D- or L-proline has 
been studied, its N-acetyl, methyl ester was found to show 
a large prevalence for a trans-amide conformation more 
akin to primary amino acids than to D- or L-proline.9 This 
makes it a potentially interesting amino acid for inclusion 
in therapeutic peptides and the basis for the design of 
fragment libraries. A number of 2-position variants of 2,4-
methanoproline have been reported recently10 and a small 
number of 4-substituted analogues, such as the 4-methyl 4 
and 4-fluoro 5 derivatives (Figure 3).9 We embarked on 
the synthesis of novel 2-substituted and 2,4-substituted 
analogues of interest in their own right but which were 
further utilised to prepare diverse N-substituted amide 
and urea parallel libraries with a view to exploring their 
utility as fragments in a screening library. The compounds 
were designed to examine the three-dimensional molecu-
lar shape and vectors produced by extended substituents 
at the N-1, 2 and 4-postions. 




Reagents and conditions: (a) Allylamine then AcCl, Et3N, 
benzene (22%); (b) hv, acetone (55%); (c) Aq. KOH (72%); 
(d) PhCOCl, Et3N, DCM, then NaH, allyl Br, DMF (80%); (e) 
hv, acetophenone, MeCN (88%); (f) 6 N HCl (99%). 
 
 
Figure 3. 4-Substituted 2,4-methanoproline analogues 
N-1, 2-substituent variations. The N-benzoyl, ethyl ester 
of 2,4-methanoproline 6 was prepared by the method of 
Malpass et al.11 This compound was used to prepare a di-
verse range of proline derivatives; the 2-hydroxylmethyl 7, 
the 2-methoxylmethyl 8 and the 2-carboxamido 9 ana-
logues (Scheme 2), from which a novel array of N-
substituted amides and ureas were prepared using parallel 
synthesis methods (Table 1). 
 




Reagents and conditions: (a) LiAlH4, THF (78%); (b) Am-
monium formate, Pd/C, EtOH (94%); (c) DIPEA, HATU, 
DCM, R1 amine (See Table 1 for yields) ; (d) 6 N HCl (76%); 
(e) NaH, MeI, THF (81%); (f) Ammonium formate, Pd/C, 
EtOH (92%); (g) 4-Isocyanopyridine, DCM (39%); (h) 





































































DCM (80%); (j) Ammonium formate, Pd/C, EtOH (90%); 
(k) 2-Flurobenzyl isocyanate, DCM (44%). 
 


























































































N-1, 2,4-substituent variations. The 4-carboxylic acid 
derivative of 2,4-methanoproline was prepared as its N-
benzoyl, 4-ethyl, 2-methyl diester 42 by the method of 
Esslinger et al.12 This compound was used to prepare the 
4-fluoromethyl derivative 43 and the 4-fluromethyl-2-
hydroxylmethyl derivative 44 (Scheme 3), from which a 
further novel array of N-substituted amides were prepared 
using parallel synthesis methods (Table 2). This sequence 
involved the selective saponification of the 4-ethyl ester in 
the presence of the 2-methyl ester using lithium hydroxide 
in a THF water mixture, followed by selective reduction of 
the carboxylic acid function and fluorination of the alcohol 
product. 
 




Reagents and conditions: (a) LiOH, THF/H2O (84%); (b) 
BH3THF, THF (84%); (c) DAST, DCM (68%); (d) TFA, H2O 
(43%); (e) DIPEA, HATU, DCM, R1 amine (See Table 2 for 
yields); (f) LiAlH4, THF then Ammonium formate, Pd/C, 
EtOH (40%). 
 






























































































In order to investigate the in-silico properties of these 
molecules, the structures were uploaded into AbbVie’s 
design platform. In addition to a range of physicochemical 
properties, the Principal Moments of Inertia (PMI) and the 
Plane of Best Fit (PBF) scores were calculated using meth-
ods described in the literature.13,14 These descriptors were 
then used in combination to map the 3-dimensional space 
of these compounds. Plotting the sum of the normalized 
PMIs versus the PBF score, the compounds within the re-
gion of the graph defined by NPR (Sum of the Normalized 
Principal Moments of Inertia (NPR1 and NPR2)) ≥ 1.07 and 
PBF Score ≥ 0.6 are deemed, by Firth et al, to reside in 3D 
space by virtue of two independent 3D descriptors. Figure 
4 shows this plot for 54 of the bridged pyrrolidines, with 
the corresponding unfunctionalized methanoproline in-
termediates labelled. Note that the shape was assigned 
using an approximation based on the relative values of 
NPR1 and NPR2.   
     
    
Figure 4. Plot of the normalized PMI versus PBF score for all 
54 fragments. 
 
All but 5 of these fragments sit in 3D space with all of the 
intermediates resting comfortably in this region of space.  
A comparison of the relative level of 3-dimensionality with 
other fragments within the AbbVie Ro3 fragment collection 






























Figure 5. The % of compounds in 3D space for AbbVie’s Ro3 
fragment library vs bridged pyrrolidines.  
 
Overall the % of 3D character of the bridged pyrrolidines is 
significantly higher (91%) than that of the broader AbbVie 
Rule of 3 (Ro3) collection (58%) which is testament to the 
proclivity of this scaffold to produce compounds with a 
higher degree of 3D character within Ro3 chemical space. 
This is similar to pyrrolidines which are common scaffolds 
in drugs and known to enhance the 3D nature of frag-
ments, with enabling chemistries employed to maximize 
both 2 and especially 3D diversity of fragment space.15 It is 
interesting to note that the unsubstituted methanoproline 
intermediates are highly saturated with proportionate 
levels of Fsp3, however for the majority of the correspond-
ing substituted amide products, the level of 3 dimensional-
ity increases as the level of saturation decreases. 
 
 
Figure 6. Comparison of Fsp3 versus PBF score for the meth-
anoprolinol (compound 7) derived series.   
 
As an example, we analysed the series of compounds from 
the methanoprolinol derivative (compound 7) and plotted 
Fsp3 versus PBF score. While the unsubstituted prolinol is 
fully saturated (Fsp3=1), the corresponding amide prod-
ucts have lower levels of saturation (Fsp3 <1), however in 
many cases they possess higher degrees of 3-
dimensionality (see Figure 5). The 3D structures of the 
corresponding conformations used to calculate the 3D de-
scriptors were visualized using Cresset’s ForgeTM platform. 
It was evident from these 3D structures why compound 19 
possessed a higher degree of 3D character with a sphere-
like conformation, while compound 13 is a flatter, more 
rod-like shape. This demonstrates that Fsp3 should be used 
with caution when describing the relative 3-dimensionality 
of compounds Overall these bridged pyrrolidines possess 
inherent 3D character and allow for the addition of frag-
ments with higher degrees of favorable 3-dimesionality. In 
addition, this method opens the door to prospective tailor-
ing of the 3D character of the fragment library prior to 
synthesis.    
 
Conclusion. Over the coming 5-10 years the predicted 
positive impact of researchers synthesizing compounds 
with higher Fsp3 in drug discovery programs will become 
further apparent. Photocycloaddition reactions stand to 
play a significant part in generating highly desirable tem-
plates such as the 2,4-methanoproline derivatives covered 
here. Our computational analysis clearly demonstrates that 
fragments derived from 2,4-methanoproline have inherent 
3D character using two independent 3D descriptors (PMI 
and PBF Score) and that the degree of shape and 3D char-
acter may be prospectively designed and biased towards 
fragments with enhanced 3D character, residing in distinct 
property space to that largely occupied by conventional 




The supporting information is available free of charge on the 
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